Medication info
Lanprazole Capsule (Lansoprazole Granules)

Lanprazole Capsule (Lansoprazole Granules)

Prescription medicationHard capsuleOral
Ingredient · strength
Lansoprazole Granules›353mg / 1 capsule
Manufacturer / importer
PharmGen Science Co., Ltd.
Appearance
A hard capsule consisting of a white upper and lower part filled with white-light brown granules.
Packaging
30 capsules/bottle
Approval status
Active

MFDS item code 200402469 · Notified 2004.02.23 · Insurance code 670100240

Summary

Main use
Treatment and prevention of ulcers, Helicobacter pylori eradication, reflux disease, and pathological gastric acid hypersecretion
Who takes it
Adults · Children
Adult dose
This drug should be administered before meals. For patients who have difficulty swallowing the medication, open the capsule, mix the contents with a small amount (60 mL) of orange juice or tomato juice, and administer immediately. To ensure that the entire dose is taken, rinse the glass with twice or more the amount of juice and drink immediately. Do not chew or crush the contents after opening this drug. 1. Short-term treatment of active duodenal ulcers: Administer lansoprazole 15 mg orally once daily for 4 weeks. 2. Short-term treatment of active benign gastric ulcers: Administer lansoprazole 30 mg orally once daily for 8 weeks. 3. Eradication of Helicobacter pylori to prevent recurrence of duodenal ulcers 1) Administer lansoprazole 30 mg with clarithromycin 250 ∼ 500 mg and amoxicillin 1,000 mg twice daily (every 12 hours) for 7 days. If necessary, treatment may be continued for up to 14 days. 2) Administer lansoprazole 30 mg with amoxicillin 1,000 mg three times daily (every 8 hours) for 14 days. 4. Maintenance therapy after treatment of duodenal ulcers: Administer lansoprazole 15 mg orally once daily. The comparative clinical trial period did not exceed 12 months. 5. Treatment of NSAID-induced gastric ulcers: Administer lansoprazole 30 mg orally once daily for 8 weeks. The comparative clinical trial period did not exceed 8 weeks. 6. Reduction of the risk of NSAID-induced gastric ulcers: Administer lansoprazole 15 mg orally once daily for 12 weeks. The comparative clinical trial period did not exceed 12 weeks. 7. Short-term treatment of symptoms associated with gastroesophageal reflux disease Administer lansoprazole 15 mg orally once daily for 8 weeks. 8. Short-term treatment of erosive reflux esophagitis: Administer lansoprazole 30 mg orally once daily for 8 weeks. 9. Maintenance therapy after treatment of erosive reflux esophagitis: Administer lansoprazole 15 mg orally once daily. 10. Pathological hypersecretory conditions, including Zollinger-Ellison syndrome The lansoprazole dosage for pathological hypersecretory conditions varies by patient. The usual starting dose for adults is 60 mg once daily. The dose should be adjusted according to the patient's needs and may be continued as long as it is clinically effective. Doses of 90 mg per dose twice daily have been administered. If the daily dose exceeds 120 mg, it should be given in divided doses. Because clearance of this drug is reduced in elderly patients, dose adjustment is necessary. Do not exceed a daily dose of 30 mg. In patients with hepatic impairment, metabolism and excretion of this drug may be delayed; administer with caution, including dose adjustment as appropriate.
Child dose
Children and adolescents aged 12 ∼ 17 years, short-term treatment of symptoms associated with non-erosive gastroesophageal reflux disease: 15 mg once daily for 8 weeks Children and adolescents aged 12 ∼ 17 years, short-term treatment of erosive reflux esophagitis: 30 mg once daily for 8 weeks Children aged 1 ∼ 11 years, weighing 30 kg or less: 15 mg once daily for 12 weeks Children aged 1 ∼ 11 years, weighing more than 30 kg: 30 mg once daily for 12 weeks

Ingredients

Manufacturer
PharmGen Science Co., Ltd.

Efficacy & effects

Treatment and prevention of ulcers, Helicobacter pylori eradication, reflux disease, and pathological gastric acid hypersecretion

  • Active duodenal ulcers
  • active benign gastric ulcers
  • duodenal ulcers
  • NSAID-induced gastric ulcers
  • symptoms related to gastroesophageal reflux disease
  • erosive esophagitis
  • Zollinger-Ellison syndrome
  • pathological hypersecretion states.
View approved original text

This medication is used for short-term treatment of active duodenal ulcers and active benign gastric ulcers. It also helps eradicate Helicobacter pylori infection to prevent recurrence of duodenal ulcers. After treatment, it can be used for maintenance therapy to prevent the recurrence of duodenal ulcers and erosive esophagitis. It is effective for treating NSAID-induced gastric ulcers and reducing occurrence risks. It is also used for the short-term treatment of symptoms related to gastroesophageal reflux disease and erosive esophagitis. Additionally, it is applied to pathological hypersecretion states, including Zollinger-Ellison syndrome, aiding in symptom improvement.

How to take

Adult dose

This drug should be administered before meals. For patients who have difficulty swallowing the medication, open the capsule, mix the contents with a small amount (60 mL) of orange juice or tomato juice, and administer immediately. To ensure that the entire dose is taken, rinse the glass with twice or more the amount of juice and drink immediately. Do not chew or crush the contents after opening this drug. 1. Short-term treatment of active duodenal ulcers: Administer lansoprazole 15 mg orally once daily for 4 weeks. 2. Short-term treatment of active benign gastric ulcers: Administer lansoprazole 30 mg orally once daily for 8 weeks. 3. Eradication of Helicobacter pylori to prevent recurrence of duodenal ulcers 1) Administer lansoprazole 30 mg with clarithromycin 250 ∼ 500 mg and amoxicillin 1,000 mg twice daily (every 12 hours) for 7 days. If necessary, treatment may be continued for up to 14 days. 2) Administer lansoprazole 30 mg with amoxicillin 1,000 mg three times daily (every 8 hours) for 14 days. 4. Maintenance therapy after treatment of duodenal ulcers: Administer lansoprazole 15 mg orally once daily. The comparative clinical trial period did not exceed 12 months. 5. Treatment of NSAID-induced gastric ulcers: Administer lansoprazole 30 mg orally once daily for 8 weeks. The comparative clinical trial period did not exceed 8 weeks. 6. Reduction of the risk of NSAID-induced gastric ulcers: Administer lansoprazole 15 mg orally once daily for 12 weeks. The comparative clinical trial period did not exceed 12 weeks. 7. Short-term treatment of symptoms associated with gastroesophageal reflux disease Administer lansoprazole 15 mg orally once daily for 8 weeks. 8. Short-term treatment of erosive reflux esophagitis: Administer lansoprazole 30 mg orally once daily for 8 weeks. 9. Maintenance therapy after treatment of erosive reflux esophagitis: Administer lansoprazole 15 mg orally once daily. 10. Pathological hypersecretory conditions, including Zollinger-Ellison syndrome The lansoprazole dosage for pathological hypersecretory conditions varies by patient. The usual starting dose for adults is 60 mg once daily. The dose should be adjusted according to the patient's needs and may be continued as long as it is clinically effective. Doses of 90 mg per dose twice daily have been administered. If the daily dose exceeds 120 mg, it should be given in divided doses. Because clearance of this drug is reduced in elderly patients, dose adjustment is necessary. Do not exceed a daily dose of 30 mg. In patients with hepatic impairment, metabolism and excretion of this drug may be delayed; administer with caution, including dose adjustment as appropriate.

Child dose

Children and adolescents aged 12 ∼ 17 years, short-term treatment of symptoms associated with non-erosive gastroesophageal reflux disease: 15 mg once daily for 8 weeks Children and adolescents aged 12 ∼ 17 years, short-term treatment of erosive reflux esophagitis: 30 mg once daily for 8 weeks Children aged 1 ∼ 11 years, weighing 30 kg or less: 15 mg once daily for 12 weeks Children aged 1 ∼ 11 years, weighing more than 30 kg: 30 mg once daily for 12 weeks

Precautions

This drug should not be administered to patients who are allergic to specific components, particularly those with hypersensitivity to this drug or benzimidazole derivatives, or who are allergic to penicillin or macrolide antibiotics. Pregnant women and patients with genetic metabolic disorders such as lactose intolerance should not take this medication. Additionally, patients with a history of drug hypersensitivity, poor liver function, elderly patients, lactating women, and children should use this medication with caution. This drug may cause various serious side effects, including severe allergic reactions, blood abnormalities, liver dysfunction, skin conditions, pneumonia, and nephritis, so if symptoms appear, consulting a doctor immediately is essential. Long-term use may lead to nutritional deficiencies such as vitamin B12 deficiency or hypomagnesemia, so regular testing is necessary. Also, when symptoms suggesting gastric cancer or malignant tumors are present, malignancy must be confirmed before administration. This drug may interact with other medications; therefore, if you are currently taking any medications, be sure to inform your physician or pharmacist. Special caution is necessary when used with HIV treatments, certain antibiotics, anticoagulants, immunosuppressants, antifungals, etc. Dizziness, drowsiness, and visual disturbances may occur during use, so caution should be exercised while driving or operating machinery. In case of overdose, blood dialysis will not remove the drug, so you must immediately visit a hospital for appropriate treatment. Keep this medication out of the reach of children and do not transfer it to other containers. It is also fragile, so care should be taken during administration.

Side effects

Anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute interstitial nephritis, urticaria, generalized rash, facial edema, dyspnea, shock, pancytopenia, agranulocytosis, hemolytic anemia, granulocytopenia, thrombocytopenia, anemia, jaundice, elevated AST, elevated ALT, toxic liver dysfunction, toxic epidermal necrolysis, Stevens-Johnson syndrome, DRESS syndrome, interstitial pneumonia, fever, cough, abnormal lung sounds, interstitial nephritis, acute renal failure, membranous colitis, bloody stool, abdominal pain, diarrhea, headache, abdominal distension, allergic reaction, back pain, weakness, candidiasis, carcinoma, chills, chest pain, edema, fever, flu-like symptoms, bad breath, infection, malaise, nuchal rigidity, pelvic pain, angina pectoris, arrhythmia, bradycardia, tachycardia, cerebrovascular accident, cerebral infarction, hypertension, hypotension, migraine, myocardial infarction, palpitations, vasodilation, syncope, asthma, bronchitis, increased cough, epistaxis, hemoptysis, hiccups, pneumonia, upper respiratory tract infection, laryngeal tumor, pulmonary fibrosis, pharyngitis, pleural disorders, respiratory disorders, rhinitis, sinusitis, wheezing, acne, hair loss, pruritus, rash, urticaria, contact dermatitis, dry skin, nail disease, skin cancer, skin disorders, sweating, abnormal vision, amblyopia, blepharitis, cataract, conjunctivitis, dry eye, ear disorders, eye disorders, glaucoma, olfactory dysfunction, photophobia, retinitis, loss of taste, blurred vision, deafness, eye pain, otitis media, taste distortion, tinnitus, visual field constriction, urinary disorders, renal colic, penile disorders, testicular disorders, urethral pain, polyuria, urinary frequency, residual urine, menstrual irregularities, chest tenderness, chest expansion, gynecomastia, diabetes, hematuria, erectile dysfunction, nephrolithiasis, hepatotoxicity, pancreatitis, taste abnormalities, aplastic anemia, leukopenia, thrombocytopenic purpura, eosinophilia, hypomagnesemia, Clostridium difficile-induced diarrhea, fracture, myositis, erythema multiforme, acute generalized exanthematous pustulosis, speech disorder, urinary retention, elevated ALP, elevated LDH, elevated γ-GTP, weakness, hyponatremia, elevated total cholesterol, elevated uric acid, tongue paralysis, lip paralysis, limb paralysis, abdominal pain, dyspnea, abdominal bloating, nausea, vomiting, stomatitis, glossitis, thirst, heartburn, gastroesophageal reflux, anorexia, neutropenia, leukocytosis, thrombocytopenia, rash, itching, drowsiness, dizziness, insomnia, paralysis, depressive state, elevated triglycerides, positive urine protein, positive urine glucose, malaise, elevated AST, elevated ALT, increased creatinine, elevated globulin, abnormal WBC, abnormal AG ratio, abnormal RBC, hyperbilirubinemia, abnormal serum potassium, increased urinary potassium, crystalluria, decreased hemoglobin, hyperlipidemia, electrolyte abnormalities, cholesterol abnormalities, increased glucocorticoids, increased LDH, abnormal platelets, increased gastrin concentration, positive fecal occult blood, albuminuria, hematuria

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it must be stored in a tightly sealed container. It is recommended to maintain storage temperatures between 1°C and 30°C. Proper storage can help maintain the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

A hard capsule consisting of a white upper and lower part filled with white-light brown granules.

Package unit

30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.